Home › Fibrolamellar hepatocellular carcinoma
Fibrolamellar hepatocellular carcinoma clinical trials recruiting in the U.S.
5 studies for Fibrolamellar hepatocellular carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Oct 5, 2026 · NCT07430202Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated May 19, 2026 · NCT05468359Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RecruitingPhase 2
Ages 0 to 30 · All sexes · Updated Feb 24, 2026 · NCT04134559DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Feb 12, 2026 · NCT06027086DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Dec 3, 2025 · NCT04248569From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.